Alunbrig (brigatinib) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Alunbrig (brigatinib) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Alunbrig (brigatinib) is a targeted therapy known as an anaplastic lymphoma kinase (ALK) inhibitor, primarily used to treat non-small cell lung cancer (NSCLC) in patients whose tumors have an ALK mutation. Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate that combines an anti-HER2 antibody with a chemotherapy drug, used to treat HER2-positive breast cancer and, more recently, HER2-positive gastric cancer. The choice between Alunbrig and Enhertu would depend on the specific cancer type and genetic markers of the tumor; therefore, a patient should consult with their oncologist to determine which medication is appropriate based on their individual diagnosis and molecular testing results.
Difference between Alunbrig and Enhertu
| Metric | Alunbrig (brigatinib) | Enhertu (fam-trastuzumab deruxtecan-nxki) |
|---|---|---|
| Generic name | Brigatinib | Fam-trastuzumab deruxtecan-nxki |
| Indications | Non-small cell lung cancer (NSCLC) | HER2-positive breast cancer, HER2-positive gastric cancer |
| Mechanism of action | ALK inhibitor | HER2-directed antibody and topoisomerase inhibitor conjugate |
| Brand names | Alunbrig | Enhertu |
| Administrative route | Oral | IV infusion |
| Side effects | Nausea, diarrhea, fatigue, cough | Nausea, fatigue, vomiting, alopecia |
| Contraindications | Hypersensitivity to brigatinib | Hypersensitivity to fam-trastuzumab deruxtecan-nxki |
| Drug class | Tyrosine kinase inhibitor | Antibody-drug conjugate |
| Manufacturer | Takeda Pharmaceuticals | Daiichi Sankyo and AstraZeneca |
Efficacy
Alunbrig (brigatinib) Efficacy in Lung Cancer
Alunbrig (brigatinib) is a targeted therapy approved for the treatment of non-small cell lung cancer (NSCLC) with a specific genetic alteration known as anaplastic lymphoma kinase (ALK) positive. The efficacy of Alunbrig in treating ALK-positive NSCLC has been demonstrated in several clinical trials. Notably, the ALTA-1L trial, which compared brigatinib to crizotinib in ALK-positive NSCLC patients who had not received prior ALK inhibitor therapy, showed that brigatinib significantly improved progression-free survival. Patients treated with brigatinib experienced a median progression-free survival of 24 months compared to 11 months for those on crizotinib, indicating a strong efficacy in delaying disease progression.
In addition to the ALTA-1L trial, the efficacy of Alunbrig has been observed in patients who have progressed on crizotinib, which is another ALK inhibitor. In these cases, brigatinib has demonstrated a high overall response rate, with a significant proportion of patients achieving partial or complete responses. This suggests that Alunbrig can be effective in patients who have developed resistance to first-line ALK inhibitors.
Enhertu (fam-trastuzumab deruxtecan-nxki) Efficacy in Lung Cancer
Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate that targets HER2, a protein that can promote the growth of cancer cells. While traditionally associated with breast cancer, HER2 mutations are also present in a subset of non-small cell lung cancers. The efficacy of Enhertu in HER2-mutant NSCLC was evaluated in a phase 2 trial, where it demonstrated promising results. Patients with HER2-mutant NSCLC who were treated with Enhertu showed a notable response rate, with a significant number of patients experiencing tumor shrinkage.
Moreover, the duration of response and progression-free survival in patients treated with Enhertu were considered clinically meaningful, offering a new therapeutic option for this specific group of lung cancer patients. The data from the trial support the use of Enhertu in the treatment of patients with NSCLC who have HER2 mutations and have received prior therapies. The drug's efficacy in this setting provides an important advancement for a group of patients with limited treatment options.
Regulatory Agency Approvals
Alunbrig
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Enhertu
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Alunbrig or Enhertu today
If Alunbrig or Enhertu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us